ATE538650T1 - Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht - Google Patents
Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewichtInfo
- Publication number
- ATE538650T1 ATE538650T1 AT07758206T AT07758206T ATE538650T1 AT E538650 T1 ATE538650 T1 AT E538650T1 AT 07758206 T AT07758206 T AT 07758206T AT 07758206 T AT07758206 T AT 07758206T AT E538650 T1 ATE538650 T1 AT E538650T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- obesity
- cannabinoid receptor
- treatment
- inverse agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78148506P | 2006-03-10 | 2006-03-10 | |
PCT/US2007/063631 WO2007106721A2 (en) | 2006-03-10 | 2007-03-09 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE538650T1 true ATE538650T1 (de) | 2012-01-15 |
Family
ID=38510173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07758206T ATE538650T1 (de) | 2006-03-10 | 2007-03-09 | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht |
Country Status (8)
Country | Link |
---|---|
US (2) | US7687481B2 (de) |
EP (1) | EP1993560B1 (de) |
JP (1) | JP4851546B2 (de) |
CN (1) | CN101437398A (de) |
AT (1) | ATE538650T1 (de) |
AU (1) | AU2007226673A1 (de) |
CA (1) | CA2647031A1 (de) |
WO (1) | WO2007106721A2 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007112688A (ru) * | 2004-09-06 | 2008-10-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia |
JP2009541283A (ja) * | 2006-06-20 | 2009-11-26 | アストラゼネカ アクチボラグ | 治療薬 |
GB0622569D0 (en) * | 2006-11-11 | 2006-12-20 | 7Tm Pharma As | Cannabinoid receptor modulators |
CA2673359A1 (en) * | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Cb1 receptor modulators |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
KR20100091255A (ko) * | 2007-12-10 | 2010-08-18 | 7티엠 파마 에이/에스 | 카나비노이드 수용체 조절자 |
KR20100098563A (ko) * | 2007-12-18 | 2010-09-07 | 사노피-아벤티스 | 아제티딘 유도체, 그의 제법 및 치료에서의 그의 적용 |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
KR20230085944A (ko) * | 2008-03-18 | 2023-06-14 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 (pgi2) 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
ES2349838B1 (es) * | 2009-05-04 | 2011-11-15 | Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im | Derivados de pirazol bivalentes como inhibidores de ingesta |
DE102009036604A1 (de) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung |
CN102260246B (zh) * | 2010-05-28 | 2014-08-13 | 范如霖 | 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用 |
EP2642856B1 (de) * | 2010-11-24 | 2017-07-19 | The Ohio State University Research Foundation | Integrin-gekoppelte kinasehemmer |
CN102603713B (zh) * | 2011-01-25 | 2014-05-14 | 范如霖 | 手性cb1受体抑制剂、制备方法及其医学用途 |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
CN102212058B (zh) * | 2011-04-14 | 2014-04-02 | 范如霖 | “单一的复合药”:手性含氮杂环酯、合成法及其在制备低毒性cb1受体抑制剂中的应用 |
CN103554025B (zh) * | 2011-05-12 | 2016-08-10 | 范如霖 | 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用 |
CN102250006B (zh) * | 2011-05-12 | 2014-03-05 | 范如霖 | 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用 |
WO2012174362A1 (en) * | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
HUE028418T2 (en) | 2011-07-26 | 2016-12-28 | Sanofi Sa | 3-Heteroaroylamino-propionic acid derivatives and their use as medicaments |
BR112013013490B1 (pt) | 2011-09-30 | 2019-10-22 | National Health Research Institutes | compostos e composição farmacêutica |
BR102012017421A2 (pt) | 2012-07-13 | 2015-04-14 | Proteimax Biotecnolgia Ltda | Peptídeo, composicão farmacêutica, ligante de receptor cb, metodo para modular a funcao de receptor cb, uso, método para o tratamento de obesidade, e, método para promover a redução de peso estetica em um indivíduo |
AU2015269247B2 (en) | 2014-06-06 | 2019-10-24 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
US10100059B2 (en) | 2015-12-09 | 2018-10-16 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
EP3279197A1 (de) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnose, behandlung und vorbeugung von zuständen, die mit dem neurotensin-rezeptor verbunden sind |
AU2017343638B2 (en) | 2016-10-12 | 2021-12-09 | Research Triangle Institute | Heterocyclic apelin receptor (APJ) agonists and uses thereof |
IL273868B1 (en) * | 2016-10-13 | 2024-03-01 | Proteimax Biotecnologia Ltda | Use of a compound, a synthetic intermediate, a pharmaceutical preparation and a therapeutic method of neuromodulation |
KR101974414B1 (ko) * | 2017-09-12 | 2019-05-02 | 주식회사 티에스디라이프사이언스 | 1h-피라졸-3-아마이드계 화합물 유도체를 포함하는 섬유증 예방 또는 치료용 조성물 |
AU2019213694B2 (en) * | 2018-01-30 | 2023-04-06 | Pi Industries Ltd. | Novel anthranilamides, their use as insecticide and processes for preparing the same. |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020148760A1 (en) * | 2019-01-15 | 2020-07-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cb1r receptor blockers with acyclic backbones |
WO2022164239A1 (ko) * | 2021-01-28 | 2022-08-04 | 주식회사 파미노젠 | 피라졸-카르복스아미드 유도체 화합물 및 이의 용도 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
EP1749002B1 (de) | 2004-05-10 | 2009-05-27 | F.Hoffmann-La Roche Ag | Pyrrol- bzw. imidazolamide zur behandlung von obesitas |
US20080146614A1 (en) | 2004-12-23 | 2008-06-19 | Leifeng Cheng | Therapeutic Agents |
EP1928859A1 (de) | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazolderivate als modulatoren des cannabinoidrezeptors |
US7872006B2 (en) | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
GB0622569D0 (en) | 2006-11-11 | 2006-12-20 | 7Tm Pharma As | Cannabinoid receptor modulators |
BR112013030793A2 (pt) | 2011-07-01 | 2016-12-06 | Inst De Pesquisas Tecnológicas Do Estado De São Paulo | processo de recuperação de liga lantanídeo-metal-metalóide em pó nanoparticulado com recuperação magnética e produto |
-
2007
- 2007-03-09 CN CNA2007800165996A patent/CN101437398A/zh active Pending
- 2007-03-09 AU AU2007226673A patent/AU2007226673A1/en not_active Abandoned
- 2007-03-09 JP JP2008558543A patent/JP4851546B2/ja not_active Expired - Fee Related
- 2007-03-09 US US11/684,016 patent/US7687481B2/en not_active Expired - Fee Related
- 2007-03-09 CA CA002647031A patent/CA2647031A1/en not_active Abandoned
- 2007-03-09 EP EP07758206A patent/EP1993560B1/de not_active Not-in-force
- 2007-03-09 WO PCT/US2007/063631 patent/WO2007106721A2/en active Application Filing
- 2007-03-09 AT AT07758206T patent/ATE538650T1/de active
-
2010
- 2010-02-06 US US12/701,528 patent/US8088798B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009529540A (ja) | 2009-08-20 |
WO2007106721A2 (en) | 2007-09-20 |
JP4851546B2 (ja) | 2012-01-11 |
US7687481B2 (en) | 2010-03-30 |
EP1993560B1 (de) | 2011-12-28 |
US20070213302A1 (en) | 2007-09-13 |
CN101437398A (zh) | 2009-05-20 |
EP1993560A4 (de) | 2010-06-02 |
US8088798B2 (en) | 2012-01-03 |
US20100144791A1 (en) | 2010-06-10 |
AU2007226673A1 (en) | 2007-09-20 |
CA2647031A1 (en) | 2007-09-20 |
EP1993560A2 (de) | 2008-11-26 |
WO2007106721A3 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
WO2007131219A3 (en) | Cannabinoid receptor antagonists/inverse agonists | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
TNSN07161A1 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
NO20090624L (no) | Forbindelser som modulerer CB2 receptoren | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
NO20083011L (no) | Modulatorer av muskarine receptorer | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
ATE489088T1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
TW200730168A (en) | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | |
MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
UA112514C2 (uk) | АНТАГОНІСТИ C5aR | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
TW200621244A (en) | Modulators of muscarinic receptors | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
JO2645B1 (en) | Vehicles | |
ATE505191T1 (de) | Ectoin zur behandlung von vascular leaks | |
IL193479A0 (en) | Modulators of muscarinic receptors |